Eric Suan
Impact in
- Ophthalmology top 1%
- Retinal Diseases and Treatments
- Ocular Diseases and Behçet’s Syndrome
Papers in
-
- Retinal Diseases and Treatments 11
- Journals
- The Lancet (3 papers)Japanese Journal of Ophthalmology (2 papers)Ophthalmology (2 papers)Ophthalmology Retina (2 papers)JAMA Ophthalmology (1 paper)
- Partner nations
- United States
In The Last Decade
Eric Suan
9 papers receiving 850 citations
Eric Suan's Hit Papers
Peers
Comparison fields: 5 of 25
- Ophthalmology 639
- Health Informatics 5
- Toxicology 8
- Pharmaceutical Science 9
- Immunology 22
Countries citing papers authored by Eric Suan
This map shows the geographic impact of Eric Suan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Suan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Suan more than expected).
Fields of papers citing papers by Eric Suan
This network shows the impact of papers produced by Eric Suan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Suan. The network helps show where Eric Suan may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials Hit paper breakdown → | 2023 | 319 |
| 2 | Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial Hit paper breakdown → | 2023 | 230 |
| 3 | TENAYA and LUCERNE Hit paper breakdown → | 2024 | 125 |
| 4 | Faricimab Treat-and-Extend for Diabetic Macular Edema Hit paper breakdown → | 2023 | 97 |
| 5 | Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial Hit paper breakdown → | 2024 | 75 |
| 6 | 2024 | 23 | |
| 7 | 2023 | 14 | |
| 8 | 2025 | 1 | |
| 9 | 2026 | 1 | |
| 10 | 2025 | 0 | |
| 11 | 2026 | 0 |
About Eric Suan
Eric Suan is a scholar working on Ophthalmology, Nuclear Energy and Engineering, Waste Management and Disposal, Infectious Diseases and Organic Chemistry, having authored 11 papers that have together received 885 indexed citations. Recurring topics across this work include Retinal Diseases and Treatments (11 papers). The work is most often cited by research in Ophthalmology (639 citations), Health Informatics (5 citations), Toxicology (8 citations), Pharmaceutical Science (9 citations) and Immunology (22 citations). Eric Suan has collaborated with scholars based in United States. Their work appears in journals such as The Lancet, Japanese Journal of Ophthalmology, Ophthalmology, Ophthalmology Retina and JAMA Ophthalmology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.